French drugmaker Ipsen (Euronext: IPN) posted financial results for 2012, showing that group sales rose 5.1% to 1.22 billion euros ($1.64 billion), despite a 4.3% decline to 518.5 million euros in its largest geographical region, Major Western European countries. Specialty care product turnover rose 13.6% to 862.5 million euros, while primary care sales slumped 11.9% to 324.6 million euros, negatively impacted by performance in France, down 29.7%. However, the company said that sales for the year were above the firm’s objectives.
In the fourth quarter 2012, group drug sales were stable year-on-year, driven by specialty care up 8.6%, fully offset by a decline of French primary care sales, down 17.3% year-on-year. Consolidated group sales reached 294.9 million euros, down 0.3% year-on year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze